Abstract 28: Patients Randomised to Glenzocimab Suffered Less Haemorrhagic Transformation at 24 Hours Compared to Placebo: AI-Imaging Sub-Analysis of the ACTIMIS Trial
Sign Up to like & getrecommendations! Published in 2024 at "Stroke"
DOI: 10.1161/str.55.suppl_1.28
Abstract: Introduction: ACTIMIS (NCT03803007) was a randomized phase 1b/2a clinical trial evaluating glenzocimab, a monoclonal antibody fragment targeting platelet receptor glycoprotein VI in patients with acute ischemic stroke treated by thrombolysis. Primary analysis demonstrated a reduction… read more here.
Keywords: sub analysis; analysis actimis; analysis; compared placebo ... See more keywords